Aurora Cannabis expands medical cannabis products across Canada, Europe, and Australia.

Aurora Cannabis is broadening its global medical cannabis portfolio with new product launches in Canada, Europe, and Australia, including dried flowers, pre-rolls, and pastilles. This expansion supports growing demand in regulated international markets and aligns with Aurora's medical-first strategy, leveraging its GMP-certified manufacturing network. The new products cater to patient and prescriber needs with diverse formats and reliable supply, aiming to strengthen Aurora's position in the global medical cannabis market. These launches will roll out through June 2026, reinforcing Aurora's commitment to quality and innovation.